CR10380A - Procesos de purificacion para aislar virus purificado de la estomatitis vesicular provenientes de cultivo celular. - Google Patents

Procesos de purificacion para aislar virus purificado de la estomatitis vesicular provenientes de cultivo celular.

Info

Publication number
CR10380A
CR10380A CR10380A CR10380A CR10380A CR 10380 A CR10380 A CR 10380A CR 10380 A CR10380 A CR 10380A CR 10380 A CR10380 A CR 10380A CR 10380 A CR10380 A CR 10380A
Authority
CR
Costa Rica
Prior art keywords
cell culture
vsv
purification processes
vesicular stomatitis
purified viruses
Prior art date
Application number
CR10380A
Other languages
English (en)
Inventor
Yun Kang
Mark William Cutler
Amadou Affrey Ouattara
Kristen Elissa Syvertsen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR10380A publication Critical patent/CR10380A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C12N2760/20252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Son procesos de purificacion para obtener virus de estomatitis vasicular (VSV) novedosos de pureza mejorada. Mas particularmente, en ciertas modalidades, se describe un proceso para purificar VSV del fluido de cultivo celular de un cultivo celular mamifero infectado con VSV, el proceso comprende: clarificar el fluido de cultivo celular mediante centrifugacion a baja velocidad y recuperar el VSV en el sobrenadante; filtrar el sobrenadante a traves de un filtro de 0.2 a 0.45 pm y recuperar el VSV en la solucion filtrada.
CR10380A 2006-04-20 2008-10-20 Procesos de purificacion para aislar virus purificado de la estomatitis vesicular provenientes de cultivo celular. CR10380A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79337606P 2006-04-20 2006-04-20

Publications (1)

Publication Number Publication Date
CR10380A true CR10380A (es) 2008-12-02

Family

ID=38625574

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10380A CR10380A (es) 2006-04-20 2008-10-20 Procesos de purificacion para aislar virus purificado de la estomatitis vesicular provenientes de cultivo celular.

Country Status (19)

Country Link
US (1) US7875446B2 (es)
EP (1) EP2007883B1 (es)
JP (1) JP5129805B2 (es)
KR (1) KR101385927B1 (es)
CN (1) CN101426905B (es)
AT (1) ATE539149T1 (es)
AU (1) AU2007240797B2 (es)
BR (1) BRPI0710820A2 (es)
CA (1) CA2648792C (es)
CR (1) CR10380A (es)
DK (1) DK2007883T3 (es)
ES (1) ES2377356T3 (es)
IL (1) IL194629A (es)
MX (1) MX2008013494A (es)
PL (1) PL2007883T3 (es)
PT (1) PT2007883E (es)
RU (1) RU2484135C2 (es)
SI (1) SI2007883T1 (es)
WO (1) WO2007123961A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831353B1 (en) * 2004-12-23 2012-02-29 MedImmune, LLC Non-tumorigenic mdck cell line for propagating viruses
EP2069480B1 (en) 2006-09-15 2014-03-19 MedImmune, LLC Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
AU2008266131B2 (en) * 2007-06-15 2011-10-20 Amgen Inc. Methods of treating cell culture media for use in a bioreactor
PL2195418T3 (pl) * 2007-10-02 2013-05-31 Ptc Phage Tech Center Gmbh Sposób i układ do oczyszczania na skalę przemysłową bakteriofagów z przeznaczeniem do terapii bakteriofagowej
KR20110004354A (ko) * 2007-12-21 2011-01-13 와이어쓰 엘엘씨 유전자 변형된 약독화 수포성 구내염 바이러스, 이의 조성물 및 사용 방법
US9169491B2 (en) * 2008-06-18 2015-10-27 Oxford Biomedica (Uk) Limited Virus purification
AU2009296628B2 (en) * 2008-09-24 2015-01-15 Medimmune, Llc Methods for purification of viruses
KR20110074564A (ko) * 2008-09-24 2011-06-30 메디뮨 엘엘씨 세포 배양, 바이러스 증식 및 바이러스 정제를 위한 방법
WO2010043700A1 (en) * 2008-10-17 2010-04-22 Dsm Ip Assets B.V. Clarification process at higher cell density
US20100143889A1 (en) * 2008-12-02 2010-06-10 Mayo Foundation For Medical Education And Research Rhabdoviridae virus preparations
WO2010089339A1 (en) * 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Purification of virus or viral antigens by density gradient ultracentrifugation
US8491904B2 (en) 2009-10-20 2013-07-23 Abbvie Inc. Isolation and purification of anti-IL-13 antibodies using protein A affinity chromatography
CN102191226A (zh) * 2010-03-08 2011-09-21 北京清大天一科技有限公司 细胞培养混合物的分离纯化方法
CN103052399B (zh) * 2010-08-12 2016-06-29 依生生物制药控股有限公司 用于减少病毒组合物中dna杂质的方法
TW201233803A (en) 2010-12-02 2012-08-16 Oncolytics Biotech Inc Lyophilized viral formulations
JP6034798B2 (ja) 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 液体ウイルス製剤
KR20140004231A (ko) * 2011-07-08 2014-01-10 이엠디 밀리포어 코포레이션 일회용 생명공학적 공정용의 개선된 심층 필터
US9610346B2 (en) 2012-03-23 2017-04-04 International Aids Vaccine Initiative Recombinant viral vectors
US9005888B2 (en) 2012-06-14 2015-04-14 System Biosciences, Llc Methods for microvesicle isolation and selective removal
WO2014031690A1 (en) * 2012-08-20 2014-02-27 Terumo Bct, Inc. Concentrating components of fluid circulated through a cell growth chamber
WO2014031480A1 (en) * 2012-08-24 2014-02-27 Xcellerex, Inc. Virus purification and formulation process
FR3010720B1 (fr) 2013-09-16 2017-08-11 Genethon Procede de production de virus enveloppes
FR3014901B1 (fr) * 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
AU2015264168B2 (en) * 2014-05-21 2020-03-12 Unchained Labs Systems and methods for exchange of buffer solutions
CN106857498B (zh) * 2016-12-27 2021-05-14 科兴（大连）疫苗技术有限公司 一种不含二甲基亚砜的细胞冻存保护液及其应用
CN107964037A (zh) * 2017-05-16 2018-04-27 浙江海隆生物科技有限公司 基于cho细胞表达系统的重组猪瘟e2蛋白的纯化方法及应用
CN110317832B (zh) 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
CN110317791A (zh) 2018-03-29 2019-10-11 西比曼生物科技（香港）有限公司 Gmp级无血清悬浮细胞大规模生产慢病毒的方法
CA3106297A1 (en) * 2018-07-19 2020-01-23 Helixmith Co., Ltd. Lyophilized pharmaceutical compositions for naked dna gene therapy
WO2020023612A1 (en) * 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
TW202043466A (zh) 2019-01-25 2020-12-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
CN110305850A (zh) * 2019-05-15 2019-10-08 苏州奥特铭医药科技有限公司 一种利用293细胞生产制备溶瘤病毒的方法
EP4179073A1 (en) 2020-07-10 2023-05-17 Boehringer Ingelheim International GmbH Process for producing a purified rhabdovirus from cell culture

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556556A (en) * 1984-03-23 1985-12-03 Advanced Genetics Research Institute Vaccine for the prevention of vesicular stomatitis virus infection
ES2210273T5 (es) 1994-07-18 2010-03-29 Conzelmann, Karl-Klaus, Prof. Dr. Virus con arn de cadena negativa no segmentado recombinante infeccioso.
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CN101618049A (zh) * 1997-10-09 2010-01-06 威尔斯塔特生物公司 使用病毒来治疗赘生物
ES2272053T3 (es) * 1998-02-17 2007-04-16 Schering Corporation Composiciones que comprenden virus y metodos para concentrar preparaciones de virus.
AU2002362761A1 (en) * 2001-10-09 2003-04-22 University Of Miami Generation of virus-like particles by vsv
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
US20030175688A1 (en) 2002-03-15 2003-09-18 Rukmini Pennathur-Das Method for the purification and production of oncolytic adenoviruses
WO2003093463A1 (en) * 2002-04-30 2003-11-13 Oncolytics Biotech Inc. Improved viral purification methods
EP1783212B1 (en) * 2002-05-14 2011-01-05 Merck Sharp & Dohme Corp. Methods of adenovirus purification
US20050009168A1 (en) 2003-05-12 2005-01-13 Robbins Joan Marie Methods and apparatus for Adeno associated virus purification
DE102004004043B4 (de) 2004-01-27 2013-04-18 Apanovis Biotechnologie Gmbh Reinigung von hochmolekularen Verbindungen mittels Affinitätsmembranchromatographie
US20070207461A1 (en) * 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
US8287878B2 (en) * 2004-04-09 2012-10-16 Wyeth Llc Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
WO2006011580A1 (ja) 2004-07-27 2006-02-02 Genomidea, Inc. ウイルスエンベロープの精製方法

Also Published As

Publication number Publication date
MX2008013494A (es) 2009-01-26
DK2007883T3 (da) 2012-02-06
BRPI0710820A2 (pt) 2011-08-23
SI2007883T1 (sl) 2012-02-29
IL194629A0 (en) 2011-08-01
RU2484135C2 (ru) 2013-06-10
EP2007883A2 (en) 2008-12-31
CA2648792A1 (en) 2007-11-01
CA2648792C (en) 2016-06-21
RU2008140137A (ru) 2010-05-27
JP2009534030A (ja) 2009-09-24
US20070249019A1 (en) 2007-10-25
PT2007883E (pt) 2012-02-17
AU2007240797A1 (en) 2007-11-01
KR20080111544A (ko) 2008-12-23
CN101426905B (zh) 2013-03-27
WO2007123961A2 (en) 2007-11-01
PL2007883T3 (pl) 2012-07-31
KR101385927B1 (ko) 2014-04-24
ES2377356T3 (es) 2012-03-26
US7875446B2 (en) 2011-01-25
CN101426905A (zh) 2009-05-06
EP2007883B1 (en) 2011-12-28
JP5129805B2 (ja) 2013-01-30
AU2007240797B2 (en) 2013-05-23
IL194629A (en) 2013-11-28
ATE539149T1 (de) 2012-01-15
WO2007123961A3 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
CR10380A (es) Procesos de purificacion para aislar virus purificado de la estomatitis vesicular provenientes de cultivo celular.
ATE526017T1 (de) Abscheidung von polyelektrolyten und reinigung von antikörpern
MX2007004696A (es) Metodos de purificacion viral mejorados.
EA201170067A1 (ru) Способ разделения посредством прямого осмоса
CO6251324A2 (es) Proceso de purificacion abreviado para la produccion de polisacaridos streptococcus pneumoniae en capsulas
EA201391166A1 (ru) Способ и система обработки воды, используемой для промышленных целей
MXPA06008435A (es) Proceso de manufactura de una inmunoglobulina libre de virus.
EA201992340A1 (ru) Способ очистки гиалуроновой кислоты
CN102250999A (zh) 一种花生活性肽分离纯化方法
MY158214A (en) Methyl methacrylate purification process
EA200700139A1 (ru) Способ отделения и очистки цезия-131 от карбоната бария
CN102137708A (zh) 使用中空纤维膜浓缩对剪切敏感的生物聚合物的方法
FI20002866A (fi) Menetelmä maltoosin puhdistamiseksi
EP4379052A3 (en) Mrna purification by tangential flow filtration
AR060686A1 (es) Purificacion de trombina
ATE541037T1 (de) Verfahren zur trennung und reinigung von nukleinsäure
CN103214421B (zh) 2-巯基-1-甲基咪唑的工业化生产方法
AR045836A1 (es) Proceso para preparar y purificar mesotriona
CN102229540A (zh) 注射用醋酸赖氨酸的生产方法
FR2974802B1 (fr) Procede de purification de l'acide glycolique par distillation
SE0201207L (sv) Förfarande för framställning av ett regioselektivt membran
CN102988989B (zh) 一种代血浆的膜分离精制提纯方法
CN204824431U (zh) 一种膜过滤净化装置
CN106146609A (zh) 一种利用膜分离技术从谷胱甘肽亚铜盐中分离提纯谷胱甘肽的方法
RU97109525A (ru) Препарат "локферон" для лечения и профилактики вирусных заболеваний и способ его получения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)